Sanjay Goel, MD, MS, discusses the safety profile of the TKI tinengotinib as a monotherapy and in combination with chemotherapy in patients with solid tumors.
Sanjay Goel, MD, MS
Advertisement
Articles by Sanjay Goel, MD, MS
Sanjay Goel, MD, MS, discusses the mechanism of action of tinengotinib and the efficacy of this agent in patients with cholangiocarcinoma.
Sanjay Goel, MD, MS, discusses the preliminary efficacy of tinengotinib monotherapy in advanced solid tumors according to data from a phase 1b/2 trial (NCT04742959).
Sanjay Goel, MD, MS, discusses the evolution of precision and personalized medicine in cancer care.
Sanjay Goel, MD, MS, discusses the need for diverse representation in clinical trials.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5